Hypertension in cancer patients treated with anti-angiogenic based regimens

Yishay Wasserstrum; Ran Kornowski; Pia Raanani; Avi Leader; Oren Pasvolsky; Zaza Iakobishvili

doi:10.1186/s40959-015-0009-4

Hypertension in cancer patients treated with anti-angiogenic based regimens

Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky, Zaza Iakobishvili^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.

Original language	English
Article number	6
Journal	Cardio-Oncology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1186/s40959-015-0009-4
State	Published - Dec 2015

Keywords

Cardiotoxicity
Hypertension
Tyrosine kinase inhibitor
VEGF
VEGF signal pathway inhibitors
VSP inhibitors
Vascular endothelial growth factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40959-015-0009-4

Cite this

@article{bb274c1ff2d74b28b2541ed59f142911,

title = "Hypertension in cancer patients treated with anti-angiogenic based regimens",

abstract = "New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.",

keywords = "Cardiotoxicity, Hypertension, Tyrosine kinase inhibitor, VEGF, VEGF signal pathway inhibitors, VSP inhibitors, Vascular endothelial growth factor",

author = "Yishay Wasserstrum and Ran Kornowski and Pia Raanani and Avi Leader and Oren Pasvolsky and Zaza Iakobishvili",

note = "Publisher Copyright: {\textcopyright} 2015, Wasserstrum et al.",

year = "2015",

month = dec,

doi = "10.1186/s40959-015-0009-4",

language = "אנגלית",

volume = "1",

journal = "Cardio-Oncology",

issn = "2057-3804",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Hypertension in cancer patients treated with anti-angiogenic based regimens

AU - Wasserstrum, Yishay

AU - Kornowski, Ran

AU - Raanani, Pia

AU - Leader, Avi

AU - Pasvolsky, Oren

AU - Iakobishvili, Zaza

PY - 2015/12

Y1 - 2015/12

N2 - New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.

AB - New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.

KW - Cardiotoxicity

KW - Hypertension

KW - Tyrosine kinase inhibitor

KW - VEGF

KW - VEGF signal pathway inhibitors

KW - VSP inhibitors

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85012214225&partnerID=8YFLogxK

U2 - 10.1186/s40959-015-0009-4

DO - 10.1186/s40959-015-0009-4

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:85012214225

SN - 2057-3804

VL - 1

JO - Cardio-Oncology

JF - Cardio-Oncology

IS - 1

M1 - 6

ER -

Hypertension in cancer patients treated with anti-angiogenic based regimens

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this